Estrogen replacement therapy following treatment for stage I endometrial carcinoma

Lee, Roger B.; Burke, Thomas W.; Park, Robert C.

doi:10.1016/0090-8258(90)90171-g

Cited by 165 publications

(54 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several retrospective trials of estrogen replacement after treatment of early-stage endometrial cancer have shown no increase in tumor recurrence or cancer-related deaths. [63][64][65] However, estrogen replacement trials in postmenopausal women with no history of malignancy have shown a significantly increased risk for breast cancer.…”

Section: Hormone Replacement Therapy For Endometrial Cancersmentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Section: Hormone Replacement Therapy For Endometrial Cancersmentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

“…The effect of HRT on the recurrence risk of endometrial cancer is unknown, although several retrospective studies have pointed to an absence of adverse outcomes [1][2][3] . Limiting factors of these studies were the recruitment of patients with a good prognosis (stage I-II patients with negative lymph nodes), the lack of a control group and the retrospective type of analysis.…”

Section: Endometrial Cancermentioning

confidence: 99%

Hormonal Replacement Therapy after Gynaecological Cancer

Biglia

Mariani

Marenco

et al. 2006

Gynäkol Geburtshilfliche Rundsch

View full text Add to dashboard Cite

Thousands of women are treated each year for gynaecological cancers; many of these are already in menopause, while other younger patients will go into early menopause due to surgery, chemotherapy and/or radiotherapy to the pelvic region. The aim of this paper is to review the biological and clinical evidence in favour and against hormone replacement therapy (HRT) use after gynaecological cancers. With the exception of breast and endometrial cancer, there is no biological evidence that HRT may increase the recurrence risk. In women with previous endometrial cancer, HRT use is not supported by univocal and conclusive data to formulate specific recommendations, whereas most authors suggest that oestrogens may be used after adequate information about risks and benefits. The use of HRT in breast cancer patients is, at present, considered contra-indicated, even if results of clinical trials are not concordant. Therapeutic non-hormonal alternatives may be proposed to these patients.

show abstract

“…In contrast, in previous studies, a tendency towards a significant decrease in the frequency of relapses was seen, also longer disease-free intervals and, to some extent, also longer survival times. Indeed, so far, only five controlled studies exist [21, 22, 23, 24, 25], to our knowledge. The essential outcomes are listed in tables 2 and 3.…”

Section: Ht After Endometrial Cancer – Clinical Trialsmentioning

confidence: 99%

“…In the study performed by Lee et al [22], 44 women with ECa stage I were treated exclusively with oral CEE (0.625–1.25 mg/day, cyclically), 35% of these received sequential progestin addition (SCEPT, no details noted). Two thirds of the women started HT (ET, SCEPT) 1 year, the others later than 2 years after surgical therapy; the HT lasted on average 64 months (range from 2 months to 11 years).…”

Section: Ht After Endometrial Cancer – Clinical Trialsmentioning

confidence: 99%

Hormone Therapy after Endometrial Cancer

Mueck¹,

Seeger²

2004

Horm Res Paediatr

View full text Add to dashboard Cite

Endometrial carcinoma is listed among the absolute contra-indications to hormone therapy. After all the existing opinions so far, hormone therapy after FIGO stage I or II endometrial cancer is still thought of as a possibility, and up to now the continuous combined oestrogen/progestogen replacement therapy would be recommended. However, until today, only observational studies have been put forward. Although no study has established an increased rate of recurrences or mortality, alternatives such as phytopreparations, tibolone, or, in, particular, psychotherapeutic drugs such as venlafaxine should be considered for the relief of climacteric complaints. Progestogen-only therapy also comes particularly into question. Indeed, the wider discussion about the gestagen effects regarding the risks of breast cancer is to be considered. Generally, after hysterectomy, at least for patients with cardiovascular risk factors, the preference today is to use low-dose oestrogen therapy (patches, gels) instead of continuous combined oestrogen/progestogen replacement therapy, and this also is now recommended for patients after endometrial cancer. This is to be noted because of the risk factors for endometrial carcinomas, such as hypertension, obesity, polycystic ovary syndrome, diabetes mellitus, etc. However, each form of hormone therapy should only be exceptionally recommended, and the patients must be informed about the risks that exist and the use of alternatives.

show abstract

Estrogen replacement therapy following treatment for stage I endometrial carcinoma

Cited by 165 publications

References 3 publications

Uterine Neoplasms

Uterine Neoplasms

Hormonal Replacement Therapy after Gynaecological Cancer

Hormone Therapy after Endometrial Cancer

Contact Info

Product

Resources

About